-
1.发明申请Methods for using amino acids with affinity for the alpha2delta-protein 失效使用对alpha2delta蛋白具有亲和力的氨基酸的方法公开(公告)号：US20050124669A1
公开(公告)日：2005-06-09
申请号：US10950094
申请日：2004-09-24
申请人： Candace Bramson , George Haig , Denis Schrier , Fong Wang
发明人： Candace Bramson , George Haig , Denis Schrier , Fong Wang
IPC分类号： A61K31/197 , A61K31/198 , A61K31/275 , A61K31/44
CPC分类号： A61K31/198 , A61K31/197 , A61K31/275 , A61K31/44
摘要： This invention relates to certain β-amino acids that bind to the alpha-2-delta (α2δ) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.
摘要翻译： 本发明涉及结合钙通道的α-2-δ（α2delta）亚基的某些β-氨基酸。 这些化合物及其药学上可接受的盐可用于治疗各种精神病，疼痛和其它疾病。
-
公开(公告)号：US20060247282A1
公开(公告)日：2006-11-02
申请号：US11480010
申请日：2006-06-30
申请人： Candace Bramson , George Haig , Denis Schrier , Fong Wang
发明人： Candace Bramson , George Haig , Denis Schrier , Fong Wang
IPC分类号： A61K31/44 , A61K31/198 , A61K31/277
CPC分类号： A61K31/198 , A61K31/197 , A61K31/275 , A61K31/44
摘要： This invention relates to certain β-amino acids that bind to the alpha-2-delta (α2δ) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.
-
3.发明申请Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease 审中-公开包括用于治疗系统性疾病和疾病的TGF-β超家族成员的蛋白质的外周管理公开(公告)号：US20120258917A1
公开(公告)日：2012-10-11
申请号：US13444282
申请日：2012-04-11
IPC分类号： A61K38/18 , C07K14/475 , A61P19/08 , A61P19/02 , A61P35/00 , A61P19/04 , A61P1/16 , A61P25/16 , A61P9/10 , C07K14/51 , A61P19/10
CPC分类号： A61M5/00 , A61K9/0019 , A61K38/1841 , A61K38/1875
摘要： The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent.
摘要翻译： 本发明涉及用于完成微生物活性剂的系统递送的方法和组合物，所述生物活性剂例如但不限于TGF-和bgr的蛋白质; 超家族通过外部管理模式。 根据本发明，示例性生物活性剂是BMP-7。 本发明进一步提供骨骼疾病例如骨质疏松症的微创全身治疗以及受损或患病的非矿化组织和器官等肾脏的微创全身治疗。 本发明的实践消除了静脉内施用生物活性剂的周边部位的不良副作用。
-
4.发明申请Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease 审中-公开包括用于治疗系统性疾病和疾病的TGF-β超家族成员的蛋白质的外周管理公开(公告)号：US20100204123A1
公开(公告)日：2010-08-12
申请号：US12705259
申请日：2010-02-12
IPC分类号： A61K38/18 , A61P19/02 , A61P19/08 , A61P19/10 , A61P19/04 , A61P25/16 , A61P13/12 , A61P9/10 , A61P3/04 , A61P3/10 , A61P1/16 , A61M25/00 , A61M5/00 , A61B17/34
CPC分类号： A61M5/00 , A61K9/0019 , A61K38/1841 , A61K38/1875
摘要： The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent.
摘要翻译： 本发明涉及用于完成微生物活性剂的系统递送的方法和组合物，所述生物活性剂例如但不限于TGF-和bgr的蛋白质; 超家族通过外部管理模式。 根据本发明，示例性生物活性剂是BMP-7。 本发明进一步提供骨骼疾病例如骨质疏松症的微创全身治疗以及受损或患病的非矿化组织和器官等肾脏的微创全身治疗。 本发明的实践消除了静脉内施用生物活性剂的周边部位的不良副作用。
-
公开(公告)号：US20050009754A1
公开(公告)日：2005-01-13
申请号：US10864667
申请日：2004-06-09
申请人： Lydia Pan , Denis Schrier , David Thompson , Timothy Wright
发明人： Lydia Pan , Denis Schrier , David Thompson , Timothy Wright
IPC分类号： A61K31/00 , A61K31/401 , A61K31/437 , A61K31/44 , A61K31/444 , A61K31/455 , A61K45/06 , A61P21/00 , A61K38/04
CPC分类号： A61K45/06 , A61K31/00 , A61K31/401 , A61K31/437 , A61K31/44 , A61K31/444 , A61K31/455 , A61K2300/00
摘要： This invention is directed to a method of treating fibromyalgia in a patient which comprises administering a growth hormone secretagogue, prodrugs thereof or pharmaceutically acceptable salts of said secretagogues or said prodrugs to a patient in need thereof. The present invention provides such a method wherein the growth hormone secretagogue is a compound of Formula I: a prodrug thereof or a pharmaceutically acceptable salt of said secretagogue or said prodrug and wherein the variables HET, R3, R4, X4, R6, R7 and R8 are as defined in the specification.
摘要翻译： 本发明涉及一种治疗患者纤维肌痛的方法，该方法包括向有需要的患者施用生长激素促分泌素，其前药或所述促分泌素或所述前药的药学上可接受的盐。 本发明提供了这样的方法，其中生长激素促分泌素是式I的化合物：其前药或所述促分泌素或所述前药的药学上可接受的盐，其中变量HET，R 3，R 4，X R 4，R 6，R 7和R 8如说明书中所定义。
-
6.发明申请Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members 审中-公开包含TGF-β超家族成员的蛋白质微创系统递送的组成和方法公开(公告)号：US20100204124A1
公开(公告)日：2010-08-12
申请号：US12705367
申请日：2010-02-12
IPC分类号： A61K38/19 , A61P19/02 , A61P19/04 , A61P1/16 , A61P13/12 , A61P9/10 , A61P25/16 , A61P27/02 , A61P3/10 , A61P3/04 , A61P35/00 , A61P29/00 , A61M25/00
CPC分类号： A61K9/0019 , A61K38/1875 , C07K14/51
摘要： The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent.
摘要翻译： 本发明涉及用于全身递送最小可溶性生物活性剂的方法和组合物，所述生物活性剂例如但不限于TGF-和bgr的蛋白质; 超家族 根据本发明，示例性生物活性剂是BMP-7。本发明进一步提供骨骼疾病例如骨质疏松症的微创全身治疗以及受损或患病的非矿化组织和器官等肾脏的微创全身治疗。 本发明的实践消除了生物活性剂血管内递送部位的不良副作用。
-
7.发明授权公开(公告)号：US06887902B2
公开(公告)日：2005-05-03
申请号：US09924656
申请日：2001-08-08
IPC分类号： A61K31/195 , A61K31/197 , A01N37/12
CPC分类号： A61K31/195 , A61K31/197
摘要： GABA analogs such as gabapentin and pregabalin are useful to prevent and treat inflammatory diseases.
摘要翻译： GABA类似物如加巴喷丁和普瑞巴林可用于预防和治疗炎性疾病。
-
8.发明授权Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases 有权GABA类似物如加巴喷丁在制备用于治疗炎性疾病的药物中的用途公开(公告)号：US06329429B1
公开(公告)日：2001-12-11
申请号：US09403867
申请日：1999-10-25
IPC分类号： A01N3712
CPC分类号： A61K31/195 , A61K31/197
摘要： GABA analogs such as gabapentin and pregabalin are useful to prevent and treat inflammatory diseases.
摘要翻译： GABA类似物如加巴喷丁和普瑞巴林可用于预防和治疗炎性疾病。
-
9.发明申请METHODS FOR TREATING PAIN INDUCED BY INJURIES AND DISEASES OF AN ARTICULAR JOINT 审中-公开用于治疗由伤口引起的疼痛和关节联合疾病的方法公开(公告)号：US20110224138A1
公开(公告)日：2011-09-15
申请号：US12878716
申请日：2010-09-09
申请人： Julie Krop , Marilyn Pike , Dean Falb , Bret Shirley , Denis Schrier , Mary Elizabeth Goad
发明人： Julie Krop , Marilyn Pike , Dean Falb , Bret Shirley , Denis Schrier , Mary Elizabeth Goad
CPC分类号： A61K38/1875
摘要： Described herein are methods for using bone morphogenetic proteins (BMPs), such as OP-1 (also known as BMP-7), to treat pain caused by osteoarthritis. The methods involve administering to a patient suffering from pain caused by osteoarthritis a BMP, for example, intraarticularly by injection directly into the joint afflicted with osteoarthritis. The methods of the invention provide long-term pain relief to sufferers of osteoarthritis and can improve the functionality of the joint to which the BMP is administered.
摘要翻译： 本文描述了使用骨形态发生蛋白（BMP）如OP-1（也称为BMP-7）来治疗由骨关节炎引起的疼痛的方法。 所述方法包括向患有由骨关节炎引起的疼痛的患者施用BMP，例如通过注射直接注射到患有骨关节炎的关节中。 本发明的方法为骨关节炎患者提供长期的疼痛缓解，并且可以改善施用BMP的关节的功能。
-
公开(公告)号：US07189747B2
公开(公告)日：2007-03-13
申请号：US10602413
申请日：2003-06-23
IPC分类号： A61K31/4166 , A61K31/215 , A61K31/197
CPC分类号： A61K31/662 , A61K31/00 , A61K31/18 , A61K31/195 , A61K31/197 , A61K31/41 , A61K31/4245
摘要： The invention relates to a method of preventing or treating cartilage damage by administering a GABA analog such as, for example, a compound of Formula and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.
摘要翻译： 本发明涉及一种预防或治疗软骨损伤的方法，该方法是通过施用GABA类似物，例如其化学式及其药学上可接受的盐，其中R 1是氢或直链或支链低级 烷基，n为4〜6的整数。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.023 秒)
